CA2222103A1 - Inositolglycans having insulin-like action - Google Patents

Inositolglycans having insulin-like action

Info

Publication number
CA2222103A1
CA2222103A1 CA002222103A CA2222103A CA2222103A1 CA 2222103 A1 CA2222103 A1 CA 2222103A1 CA 002222103 A CA002222103 A CA 002222103A CA 2222103 A CA2222103 A CA 2222103A CA 2222103 A1 CA2222103 A1 CA 2222103A1
Authority
CA
Canada
Prior art keywords
alkyl
inositolglycans
insulin
action
r1r2n
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002222103A
Other languages
French (fr)
Other versions
CA2222103C (en
Inventor
Wendelin Frick
Gunter Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst Aktiengesellschaft
Wendelin Frick
Gunter Muller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft, Wendelin Frick, Gunter Muller filed Critical Hoechst Aktiengesellschaft
Publication of CA2222103A1 publication Critical patent/CA2222103A1/en
Application granted granted Critical
Publication of CA2222103C publication Critical patent/CA2222103C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inositolglycans having insulin-like action Compounds of the formula I

A-Z-R (I) are described, where A is the radical H - P(O)(OH) -, H - P(S)(OH) -, HO--P(S)(OH) -, HS-P(S)(OH) -, (C1-C4) - alkyl - P(O)(OH) -, (C1-C4) - alkyl -P(S)(OH)-, S(O)2(OR1) -, S(O)(OR1)-, NH2 - C(O) -, R1R2N -, R1R2N - C(O) -NH -, R1O - SO2 - NH -, (C1-C4) - alkyl - SO2 -, (C1-C4) - alkyl - S(O) - or R1 - S -, Z is 2 to 6 substituted or unsubstituted sugar radicals and R is substituted or unsubstituted inositol.
The compounds of the formula I are suitable for the treatment of diabetes mellitus or noninsulin-dependent diabetes.
CA002222103A 1996-11-28 1997-11-25 Inositolglycans having insulin-like action Expired - Fee Related CA2222103C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19649350.1 1996-11-28
DE19649350A DE19649350A1 (en) 1996-11-28 1996-11-28 Inositol glycans with an insulin-like effect

Publications (2)

Publication Number Publication Date
CA2222103A1 true CA2222103A1 (en) 1998-05-28
CA2222103C CA2222103C (en) 2007-08-28

Family

ID=7813041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222103A Expired - Fee Related CA2222103C (en) 1996-11-28 1997-11-25 Inositolglycans having insulin-like action

Country Status (19)

Country Link
US (1) US6004938A (en)
EP (1) EP0845475B1 (en)
JP (1) JP4299378B2 (en)
CN (1) CN1136224C (en)
AR (1) AR018246A1 (en)
AT (1) ATE290541T1 (en)
AU (1) AU728637B2 (en)
BR (1) BR9706041C1 (en)
CA (1) CA2222103C (en)
CZ (1) CZ294886B6 (en)
DE (2) DE19649350A1 (en)
DK (1) DK0845475T3 (en)
ES (1) ES2237784T3 (en)
HK (1) HK1008786A1 (en)
HU (1) HUP9702242A3 (en)
PL (1) PL188604B1 (en)
PT (1) PT845475E (en)
RU (1) RU2178794C2 (en)
TR (1) TR199701432A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
GB9814039D0 (en) * 1998-06-29 1998-08-26 Univ London Materials and methods relating to the prevention or treatment of ischaemia-reperfusion injury
CA2433857C (en) * 2000-05-12 2012-07-31 Rodaris Pharmaceuticals Limited Inositol phosphoglycan derivatives and their medical uses
EP1406913A2 (en) * 2000-05-12 2004-04-14 Rodaris Pharmaceuticals Limited Inositolglycans and their uses
US6716826B2 (en) 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US6759390B2 (en) 2000-05-12 2004-07-06 Manuel Martin-Lomas Compounds and their uses
US6953781B2 (en) 2000-05-12 2005-10-11 Rodaris Pharmaceuticals Limited Compounds and their uses
DE60133137D1 (en) * 2000-05-12 2008-04-17 Rodaris Pharmaceuticals Ltd INOSITOLPHOSPHOGLYCANDERIVATE AND ITS MEDICAL USE
US6939857B2 (en) 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
FR2828206B1 (en) * 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
WO2003092700A1 (en) 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
EP1542703A4 (en) * 2002-07-10 2007-11-07 Massachusetts Inst Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
CN100369610C (en) * 2002-10-09 2008-02-20 中国药科大学 Plant extract for preventing and treating diabetes, and preparing method and pharmaceutic use thereof
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
FR2878850B1 (en) * 2004-12-02 2008-10-31 Cis Bio Internat Sa DERIVATIVES OF INOSITOL-1-PHOSPHATE
JP5537951B2 (en) * 2006-12-21 2014-07-02 トラスティーズ・オブ・タフツ・カレッジ Synthetic lipophilic inositol glycans for the treatment of cancer and glucose metabolism disorders
CA2674048A1 (en) * 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications
EP2152085A4 (en) * 2007-05-01 2012-05-23 Normoxys Inc Erythropoietin complementation or replacement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446064A (en) * 1980-12-19 1984-05-01 The University Of Virginia Alumni Patents Foundation Insulin mediator substance
DE3326472A1 (en) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
US4906468A (en) * 1986-04-11 1990-03-06 The Rockefeller University Insulin activity messengers, their antibodies, and thereof
YU66892A (en) * 1991-08-20 1995-10-24 Hoechst Ag. PHOSPHOINOSYTOLGLICAN - A PEPTID WITH ACTION AS INSULIN
EP0545198B1 (en) * 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptides with insulin like activity
JPH06293790A (en) * 1993-04-08 1994-10-21 Kyowa Hakko Kogyo Co Ltd Physiologically active substance, inositol glucan
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances

Also Published As

Publication number Publication date
JP4299378B2 (en) 2009-07-22
EP0845475B1 (en) 2005-03-09
HUP9702242A3 (en) 1999-01-28
ATE290541T1 (en) 2005-03-15
PL323407A1 (en) 1998-06-08
EP0845475A1 (en) 1998-06-03
BR9706041C1 (en) 2000-06-06
CA2222103C (en) 2007-08-28
CZ294886B6 (en) 2005-04-13
DE19649350A1 (en) 1998-06-04
HUP9702242A1 (en) 1998-12-28
CZ377597A3 (en) 1998-06-17
HU9702242D0 (en) 1998-03-02
JPH10158291A (en) 1998-06-16
PT845475E (en) 2005-06-30
ES2237784T3 (en) 2005-08-01
PL188604B1 (en) 2005-03-31
RU2178794C2 (en) 2002-01-27
MX9709207A (en) 1998-05-31
AU728637B2 (en) 2001-01-11
DK0845475T3 (en) 2005-06-27
CN1184112A (en) 1998-06-10
CN1136224C (en) 2004-01-28
AR018246A1 (en) 2001-11-14
BR9706041A (en) 1999-11-23
AU4538297A (en) 1998-06-04
TR199701432A2 (en) 1998-06-22
US6004938A (en) 1999-12-21
DE59712220D1 (en) 2005-04-14
HK1008786A1 (en) 1999-05-21

Similar Documents

Publication Publication Date Title
CA2222103A1 (en) Inositolglycans having insulin-like action
CA2103462A1 (en) X-Ray Contrast Agent
CA2048110A1 (en) Imidazopyridine derivatives and their use
CA2060928A1 (en) Dental/medical composition and use
CA2056971A1 (en) Improved platy pigments
CA2110693A1 (en) Amino acid derivative anticonvulsant
CA2211314A1 (en) A process for preparing certain aza cyclohexapeptides
CA2205275A1 (en) Vitamin d3 analogs
AU6745696A (en) The preparation of fluorinated organic compounds
CA2166467A1 (en) Sunscreen agents
AU584426B2 (en) Compounds having a polymerizable acylurethane structure, and their production and use
CA2293361A1 (en) Process for producing 2-hydroxybenzamide derivatives
AU5000193A (en) Antithrombotic treatment with calix(n)arene compounds
IE800477L (en) Pyrimidine derivatives
CA2256620A1 (en) A process for preparing certain aza cyclohexapeptides
CA2237897A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
AU6752990A (en) Combatting slime-forming microorganisms
CA2042535A1 (en) Process for the preparation of intermediates useful for the synthesis of benzothiazepines
CA2092694A1 (en) Use of pyridylmethylsulphinyl-1h-benzimidazole derivates in the treatment of illnesses caused by helicobacter bacteria
WO1997020937A3 (en) Modification process
AU1032392A (en) Multi-pressure compensation of variable displacement pump
CA2083361A1 (en) Fish production
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
USD324312S (en) Camouflage pattern
CA2209440A1 (en) Rubber compounds containing aryl bis citraconamic acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed